Phase I/II study of dabrafenib, trametinib, and navitoclax in BRAF mutant melanoma (Phase I and II) and other solid tumors (Phase I only)
Study of Dabrafenib, Trametinib, and Navitoclax in BRAF-Mutant Melanoma and Other Solid Tumors
Sponsor: National Cancer Institute NCI
Enrolling: Male and Female Patients
IRB Number: AAAS2517
U.S. Govt. ID: NCT01989585
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of the first part (Phase I) of the study is to test the safety of navitoclax in combination with dabrafenib and trametinibat different doses to find out what effects, if any, it has on people. There will be about 18 people treated in this part of the study. The purpose of the second part of this study (Phase II) is to compare the good and bad effects of navitoclax in combination with dabrafenib and trametinib to using the usual approach of dabrafenib and trametinib in patients with BRAF-mutant melanoma. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. There will be 50 people taking part in this part of the study.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a BRAF-mutant melanoma that has spread or is unresectable? Yes No
Are you able to carry out light work (e.g. light house work or office work)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator